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ABSTRACT 
 
Active pain self-management (PSM) for patients with chronic pain (CP) is assumed to 
require multidisciplinary care, leaving prescribing analgesics the most accessible 
option for general practitioners (GPs). As such, we sought to upskill GPs in multimodal 
PSM with a harm minimisation approach for any opioid prescribing. 
Having developed an educational training resource, a multidisciplinary team (MDT) 
delivered the program to attendees at a GP conference in 2017. The educational 
package comprised pre-readings, a six-hour interactive, skills-based workshop, and 
post-workshop resources. The single-group intervention was evaluated with an 
original and unvalidated pre-/post-test (three months) survey of four domains: 
knowledge, attitudes, utilisation of strategies involving PSM and opioid harm 
minimisation. Paired t-tests were conducted on each domain score and overall, with 
effect sizes assessed using Cohen’s d. A sensitivity analysis was performed on the data 
lacking a post-test survey response. Post-survey scores were imputed using chained 
regression equations, then paired t-tests analyses were conducted on imputed 
datasets using Rubin’s method to pool estimates. 
Of 99 participants, 33 returned both surveys for primary analysis. These were 
combined in the sensitivity analysis with 60 unpaired surveys with modest internal 
consistency (Cronbach’s alpha 0.736). Primary analysis demonstrated significant self-
reported improvements in each educational domain, with the overall score increasing 
10.54 points out of 130 (p < 0.001, Cohen’s d 1.11). Improvements were similar in a 
sensitivity analysis.  
This study found that a brief GP educational package might be a viable intervention 
for facilitating PSM and promoting safer prescribing strategies. Outcomes at three 
months, from this unvalidated survey instrument, suggest improvements in 
knowledge, attitudes and self-reported facilitation of PSM and opioid prescribing. As 
this study did not measure clinician behaviour or patient outcomes objectively, further 
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educational research is indicated to confirm the findings and identify how best to 
deliver CP management training. 
 
: analgesics, opioid, chronic pain, general practice, educational 
measurement, pain management, deprescribing  
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BACKGROUND 
Pain is common, experienced in the last month by most (68%) adults in Australia, with 
15% reporting recurrent or persistent pain in the previous six months (Miller et al. 
2017). General practitioners (GPs) often manage chronic pain (CP) as if it were an acute 
condition and focus on elimination of pain rather than promotion of functional 
restoration (Schneiderhan, Clauw & Schwenk 2017; Semple & Hogg 2012; Sullivan & 
Ballantyne 2016). Historically, pain management education has been advocacy driven. 
Professor Emeritus John Bonica championed the multidisciplinary team (MDT) 
combined with interventional approaches (Loeser 2017), and Dame Cicely Saunders 
(1978), of the hospice movement, taught how the multifaceted nature of pain in 
terminal illness required attention to social, psychological and spiritual distress along 
with liberal access to opioid analgesics. Liberal access—appropriate in palliative care 
practice—was promoted for all patients for ‘under-treated’ non-cancer CP by pain 
specialists and commercial interests, despite a lack of clear scientific evidence (Sullivan 
& Ballantyne 2016). Pharmaceutical manufacturers underwrote pain advocacy 
organisations, medical societies, medical education and guideline development to 
influence prescribing culture (Davis & Carr 2016; Organisation for Economic Co-
operation and Development [OECD] 2019). Continuing medical education (CME) for 
CP claimed that ‘judicious’ opioid prescribing strategies could prevent prescription 
opioid analgesic (POA) patients from being transformed into addicts (Dyer 2019; 
Kertesz & Gordon 2018; Kuehn 2017; Madras 2018; OECD 2019). A composite model 
of CP care soon emerged, highlighting specialist multidisciplinary and interventional 
care combined with opioids titrated to symptoms (Sullivan & Ballantyne 2016). 
Consequently, over the last three decades, the availability of POAs has boomed 
across the Western world (OECD 2019). Iatrogenic harms such as opioid-related 
deaths (ORDs) increased an average of 20% across 25 OECD (2019) countries. In the 
United States (US), opioid prescribing escalated over 300% (Madras 2018), with over 
one-third (37.8%) of adults reporting POA use during 2015 (Han et al. 2017). In 
America, drug poisonings (predominantly ORDs) are now the leading contributor to 
reduced gains in life expectancy (Dowell et al. 2017; OECD 2019). The situation in 
Australia is similar, with POA dispensing increasing 15-fold from 1992 to 2012 (Blanch, 
Pearson & Haber 2014). An estimated 16% of adult Australians are being dispensed a 
POA annually (Lalic et al. 2019), with a 10-fold variation in prescribing rates across the 
nation (Australian Commission on Safety and Quality in Health Care 2015). Past or 
current POA misuse is common and, in 2016, was reported by 11% of adults (Australian 
Institute of Health and Welfare 2018). In the decade leading to 2016, the rate of ORDs 
almost doubled to three each day with over three-quarters involving POAs (Australian 
Institute of Health and Welfare 2018; Department of Health 2019). Tapering or 
termination of long-term POAs may actually increase ORDs without the introduction 
of active pain self-management (PSM) as well as strategies used for opioid 
maintenance in dependency (James et al. 2019). 
The World Health Organization recently discontinued two CP guidelines due to the 
emerging science supporting non-pharmaceutical strategies, as well as reports of 
conflicts of interest involving the experts who developed the guidance (Dyer 2019). 
Evidence informed CP management emphasises non-pharmacological and non-
invasive PSM (a multidisciplinary engagement with multimorbidity), the non-initiation 
or deprescribing of opioids, and a harm minimisation approach to addictive 
pharmacotherapies (Australian Commission on Safety and Quality in Health Care 2015; 
Department of Health 2019; Hogans et al. 2018; Holliday et al. 2018; Malfliet et al. 
2019; Manhapra & Becker 2018). The shift away from POAs reflects concerns about 
harms including pre-clinical research that indicates opioids may intensify and prolong 
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pain (Grace et al. 2016), and a prospective one-year clinical trial showing better 
outcomes from non-opioid management of musculoskeletal pain (Krebs et al. 2018). 
Most pain education supports referral to a multidisciplinary team (MDT) (White et 
al. 2019) but this is usually impractical, with less than 0.2% of those with CP accessing 
them each year (Semple & Hogg 2012). GPs often deal with patients with CP—in fact, 
discussing pain in almost half of their consultations (Tai-Seale et al. 2011). GPs are 
responsible for half of all POA initiations (Lalic et al. 2019) which are a GP’s most 
commonly prescribed (10%) initial script (NPS MedicineWise 2019). Overall, POAs 
comprise 4.4% of GP prescribing (NPS MedicineWise 2019). 
GP care may be less expensive than specialist MDTs, but considering the costs of 
lost earnings and productivity, GP care is less cost-effective (Deloitte Access Economics 
2019; Lin et al. 2011; Semple & Hogg 2012). Cost-effectiveness may be improved with 
the addition of PSM, whether delivered by a GP or accessed by referral (Lin et al. 2011). 
To date, there have been no direct comparisons of multidisciplinary care against a 
biopsychosocial approach taken in a monodisciplinary setting (Malfliet et al. 2019), so 
we simply do not know which approach is more cost-effective. However, we can make 
some assumptions based on what we know. For example, the prevalence of CP and 
opioid consumption is higher in populations with demographics characterised by low 
levels of education, low income, rurality and complex psychosocial issues (Hardman, 
Lawn & Tsourtos 2018). Such populations are less willing or able to access specialist 
MDTs and are more likely to dropout from PSM (Hardman, Lawn & Tsourtos 2018). 
That said, GPs offer greater geographical and financial accessibility along with 
opportunistic and longitudinal care. This may explain why population-level research 
shows strengthening of the GP sector improves many health outcomes, including 
mortality (Basu et al. 2019). 
In the US, the National Institutes of Health has committed to developing and 
disseminating non-addictive pain management strategies integrated with the 
prevention and treatment of addiction (Kuehn 2017). In Australia, the Department of 
Health (2019) has called for action to translate best practice CP management into 
primary care to make it accessible. The department identified a need for short training 
courses for GPs, which featured engagement activities such as webinars and 
workshops (Department of Health 2019). To equip GPs to address the biopsychosocial 
under-treatment of CP and to minimise the unsafe provision of POAs, our MDT 
developed training, compatible with standard CME scheduling, promoting strategies 
deliverable within routine clinical workflow. As the authors are not aware of any 
evaluations of similar training, we undertook this study. 
METHODS 
This paper describes a questionnaire-based evaluation of a pragmatic educational 
intervention, using a pre-/post-test design without a control group. Our working group 
included a pain physician (CHa), a pain physiotherapist (LJ), a clinical psychologist (MN) 
and a psychiatrist (NH)—all of whom specialise in CP—as well as three non-pain 
specialised GPs. All the GPs worked in private practice—two with special interests in 
mental health (CF and JG) and one as a rural GP and addiction physician (SH). 
The project was named ‘Time-efficient Management of Pain in the Office’ 
(TEMPO). It was designed to promote positive, active pain care involving multiple PSM 
micro-interventions delivered longitudinally during standard GP consultations. 
Reliance on safety strategies, derived from a non-pain dependency model, was 
recommended for any provision of POAs. Content advice was also received from the 
pain and addiction specific interest groups within the Royal Australian College of 
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General Practitioners (RACGP). During 2016–2017, the TEMPO package was delivered 
and refined in a webinar and at four conferences, and was specifically accredited by 
the RACGP as an ‘active learning module’ (ALM). Every three years, Australian GPs are 
required to obtain CME credits from such a module in which two-thirds of a six-hour 
workshop involves active learning exercises. Participants in this study were emailed 
readings before the workshop (Holliday & Jammal 2015; Lack 2016; Schneiderhan, 
Clauw & Schwenk 2017), directed to relevant websites such as the NSW Health ACI 
Pain Management Network (https://www.aci.health.nsw.gov.au/chronic-pain) or the 
Hunter Integrated Pain Service 
(http://www.hnehealth.nsw.gov.au/Pain/Pages/Health professionals.aspx). Online 
CME and patient education resources were provided subsequently  as published in 
detail previously (Holliday et al. 2018) and cited in the Australian National Strategic 
Action Plan for Pain Management (Department of Health 2019). The content is 
summarised in Box 1. 
 
BOX 1: WORKSHOP CONTENT 
• The history of pain and opioid management: acute analgesia, palliative care and 
dependency treatments 
• Opioid-related harms in chronic pain including how prescribing volume correlates 
with overdoses and addiction 
• The regulators’ view: identifying misprescribers 
• The non-initiation and de-prescribing of opioid analgesics 
• Management or prevention of the various opioid-related harms including 
dependency, naloxone rescue provision, and avoiding co-consumption with 
benzodiazepines 
• Stigma and opioid substitution therapy 
• The limited role of pharmaceuticals including medicinal cannabis 
• Over-investigation 
• Patient-centred care 
• The role of practice nurses 
• Pain active self-management 
• Biopsychosocial case formulation 
• Assessment of function and of pain outcome scores 
• Screening with 10-item Örebro 
• Patient neuro-education including central sensitisation 
• Active versus passive therapies 
• Goal setting and activity pacing 
• Cognitive behavioural therapy for pain or insomnia 
• Depression and affective disorders 
• Active relaxation: breathing and mindfulness 
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• Strategies for flare-ups 
• Addressing coping-orientated substance use 
• The endogenous opioid system: social reward and social pain 
• Social reconnection with work, family and partner or with art or spirituality 
• Couple interventions 
• Obesity-independent nutritional factors and the microbiome 
• How to operationalise PSM into time-poor general practice 
The six-hour skills-based workshop was presented by an MDT and included 16 learning 
activities. Participants undertook role-plays and small group discussions covering 
patient education, outcome assessments, deprescribing and the provision of PSM. 
Most of the workshop involved non-pharmacological management with less than an 
hour allocated to discussing POAs and other pharmacotherapy. 
The ALM ran during the RACGP national annual conference in Sydney, Australia, on 25 
October 2017. Registrants were invited to participate in the research study and 
provided with hard copy or electronic forms of the study questionnaire. 
No previously published CP education evaluation instruments covered non-
pharmacological PSM, as they related predominantly to opioid-focused paradigms of 
care. Therefore, we developed an instrument specifically for this study, informed by 
an evaluation of the US Risk Evaluation and Mitigation Strategy (REMS) program 
(Alford et al. 2016). Our instrument (Box 2) covered four domains: knowledge, 
attitudes, current utilisation of PSM strategies, and last-month use of pharmaceutical 
REMS strategies. The questionnaire was not validated, though piloted in two TEMPO 
workshops during 2016. 
Demographic factors elicited included age, gender, Prescription Shopping 
Information Service registration status and main practice site postcode (to describe 
rural versus urban status) (Department of Health 2018). A unique identifier allowed 
pairing of pre/post data. 
Questionnaires were emailed one month before the workshop. Participants could 
return the pre-workshop form by email, fax or post, or else hand-deliver it at the 
workshop. Participants were able to indicate consent for their responses to be used 
for educational research. The presenters were blind to these evaluations at the time 
of the workshop. 
The post-workshop questionnaire was delivered to all delegates at 12 weeks post-
workshop and included an invitation for qualitative feedback. There was a $20 
shopping voucher offered for the first 10 responses, and all registrants were emailed 
two reminders. Ethics approval was given by the RACGP National Research and 
Evaluation Ethics Committee (NREEC 16-005). 
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Eleven multiple-choice questions assessed knowledge of assessment, PSM and REMS, 
with one question derived from previous work (Alford et al. 2016). Each question gave 
4–6 options with the one correct answer scoring two points. Other domains utilised a 
five-point Likert scale from 0–4, with approximately one-third of items being reverse 
scored. Attitudes were assessed based on participants’ level of agreement with 11 
statements, with four of these items based on previous work (Alford et al. 2016). 
Current utilisation of PSM was assessed with nine items, and past-month REMS with 
seven. Domain sums were calculated to give maximum scores of 22, 44, 36 and 28, 
respectively, and totalled to give an overall maximum score of 130. 
Internal consistency of the instrument domains, and of the overall instrument, was 
assessed with Cronbach’s alpha. Paired t-tests were conducted on each domain score 
and on the overall score. Effect sizes for domain scoring changes were assessed with 
Cohen’s d. 
For sensitivity analysis, each domain’s item scores underwent multiple imputation. 
The pre-survey section scores, along with the respective section items, were used to 
predict the imputed post-survey section scores. The imputations were also adjusted 
for gender, Prescription Shopping Information Service registration status, age and 
practice location. The chained regression equations method was used to impute 30 
completed datasets, and results of the paired t-test were produced over the datasets 
using Rubin’s method. Paired t-tests were performed on the imputed data, as for the 
primary analysis. All analyses were conducted using SAS Version 9.4 (SAS Institute Inc, 
Cary, NC, USA). 
RESULTS 
From 99 attendees, 91 completed the pre-workshop survey. Of these, 33 participants 
(36%) completed a post-workshop survey (overall completion rate 33%). The 
demographic characteristics of the sample are presented in Table 1. Baseline 
participants had a mean age of 48 years, an even gender split, with over two-thirds 
from major urban centres, and six practicing outside Australia. 
Table 1. Demographics (Pre-workshop) 
 Statistic 
Total 





chi square P 
Age Mean 47.9 (14.4) . . 0.3644 
 Median 47 (27, 100)   0.4162 
Gender Male 45 (49%) 0.113 2 0.9450 
 Female 46 (51%)    
Remoteness 
classification 
Major city 53 (62%) 16.876 12 0.1543 
 Large regional 5 (5.9%)    
 Medium–large 
regional 
8 (9.4%)    
 Medium regional 6 (7.1%)    
 Small regional 6 (7.1%)    
 Remote 1 (1.2%)    
 Overseas 6 (7.1%)    
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 Statistic 
Total 





chi square P 
 Missing 6    
 
The instrument sub-scales assessing attitudes and utilisation of PSM and REMS had 
Cronbach’s alphas of 0.57, 0.73 and 0.41, respectively. Overall, the entire survey had 
good overall internal consistency with a Cronbach’s alpha of 0.736. 
The comparison of pre- and post-workshop scores showed increases in every 
domain and overall (Figures 1 and 2). For our primary analysis (33 paired questionnaire 
responses), there were changes of 1.6 (95%CI 0.4,2.8; p = 0.001), 2.7 (95%CI 1.28,4.1; 
p < 0.001), 4.4 (95%CI 2.6,6.2; p < 0.001) and 1.8 (95%CI 0.5,3.1; p < 0.010) for 
knowledge, attitudes, and utilisation of PSM and REMS, respectively. The Cohen’s d 
for these effect sizes for the pre–post differences by domain were 0.49, 0.68, 0.86 and 
0.48. The overall score increased by 10.5 (p < 0.001), with Cohen’s d of 1.11. 
 
Figure 1. Boxplot of pre- and post-workshop domain scores with complete 
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Figure 2. Boxplot of pre- and post-workshop overall scores (n = 33) 
 
The sensitivity analysis using imputed data (91 paired questionnaire responses) 
produced similar findings with marginally larger changes of 2.2 (95%CI 1.4,2.6; 
p = 0.001), 3.6 (95%CI 2.6,4.6; p < 0.001), 3.5 (95%CI 2.9,4.3; p < 0.001) and 2.2 (95%CI 
1.6,2.7; p < 0.001) for knowledge, attitudes, and utilisation of PSM and REMS, 
respectively. The total score increased by 11.1 (95%CI 9.1,13.3; p < 0.001). 
There were 40 comments about the beneficial aspects of training. For example, one 
respondent stated ‘it empowered me to think I can do it and gave me tools to start 
using to achieve this’ (Participant 4), while another acknowledged the ‘use of objective 
measure for function (e.g., sit-to-stand test and online resources for patients to 
understand chronic pain)’ (Participant 5). Participant 16 expressed ‘how increasing 
physical activity and providing psychoeducation may decrease a need for analgesic 
medications’, therefore, ‘providing the rationale of moving from opioids and providing 
clear alternatives to manage chronic pain’ (Participant 22). Others simply ‘enjoyed it’, 
particularly as the ‘case examples and role-plays work well’ (Participant 28), including 
the ‘simple strategies and a common-sense approach to management’ (Participant 
32). 
There were also 27 comments about areas to improve. For example, one thought 
that ‘not enough time [was] spent discussing modes to reduce dosing’ (Participant 7), 
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participant queried whether ‘there [was] online access to the presentations’, as ‘each 
speaker offered excellent strategies but there was too much to take in’ (Participant 8). 
This sentiment was echoed by Participant 52, who: 
found the information hard to translate into my older chronic pain patients and would 
appreciate a top-up education about what to do to help the elderly, or chronic pain 
patients who have been the same situation for years. I have started initiating the 
conversation with them but would appreciate more helpful tips. 
Nonetheless, some participants shared no criticisms about the training, believing 
‘it was a good session and every GP should be required to undertake the course’, 
particularly ‘GP registrars’ (Participant 40). 
DISCUSSION 
Various allied health providers have successfully trained in PSM (Nicholas & Blyth 
2016) and this evaluation suggests that GPs may do so as well. Three months after 
brief training, scores for knowledge, attitudes and self-reported practice improved for 
each measure, with moderate to large effect sizes. 
Previous evaluations of pain education for GPs have focused on the under- or 
overuse of opioids (Hogans et al. 2018; Ospina et al. 2013). Reviews indicate they lack 
consensus on content, or on how outcome measures are defined or gauged (Davis & 
Carr 2016; Hogans et al. 2018). A diversity of findings with differing evaluation 
methods was demonstrated by dual evaluations of opioid REMS training for Australian 
GP registrars. The pre-/post-test survey showed improved knowledge and reported 
practice, but the objective prescribing data revealed no reduction in total opioid 
prescription (Holliday, Hayes, Dunlop, Morgan, Tapley, Henderson, Larance, et al. 
2017; Holliday, Hayes, Dunlop, Morgan, Tapley, Henderson, van Driel, et al. 2017). In 
2015, over 7,000 Australian GPs received academic detailing, led by specialists and 
GPs, that recommended a transition from opioid prescribing to non-pharmacological 
care (NPS MedicineWise 2017). One year afterwards, a questionnaire found improved 
knowledge about prescribing, but none regarding non-pharmacological care (Deloitte 
Access Economics 2019; NPS MedicineWise 2017). In 2016, 19 GPs in New South 
Wales, Australia, and other primary health clinicians were invited to two workshops. 
These aimed to encourage deprescribing of POAs and referral to local MDTs to deliver 
regimes similar to specialist MDTs (White et al. 2019). Eleven attitudinal items were 
assessed with an unvalidated questionnaire within a pre-/post-test design. At the 
conclusion of the second two-hour workshop, six attitudinal items had improved. 
Since 2012, US pharmaceutical manufacturers have been mandated to fund REMS 
education, despite the risks for conflicts of interest (Davis & Carr 2016). Two months 
after the voluntary 2–3 hours of training, clinician knowledge and confidence had 
improved, with 86% reporting changes in practice (Alford et al. 2016). Of previously 
evaluated CP education interventions, none have focused on upskilling and 
empowering GPs to provide psychobehavioural care. 
The National Strategic Action Plan considers it vital to upskill time-poor GPs in early 
interventions, including PSM, to prevent the chronification of acute pain (Department 
of Health 2019). This study indicates such training may be considered viable. One 
report estimated that a nationwide CP education program for GPs would be cost-
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effective based solely on the reduction of ORDs (Deloitte Access Economics 2019). 
Another goal of the National Strategic Action Plan is the addressing of barriers to safer 
pharmacotherapy (Department of Health 2019), a major one of which is a perceived 
lack of effective alternatives (White et al. 2019). If further evaluations show TEMPO-
like education is effective, then the initiation, or re-triggering, of opioid-related harms 
may be reduced (Nicholas & Blyth 2016). Variability in healthcare provision also may 
be reduced as higher rates of opioid provision and overdoses are found rurally, in 
lower socio-demographic areas and among Aboriginal and Torres Strait Islander 
populations (Australian Commission on Safety and Quality in Health Care 2015; 
Penington Institute 2017). These are demographic factors shared with CP and 
multimorbidity (Barnett et al. 2012; Lujic et al. 2017). 
The facilitation of PSM is now considered a core GP competency in the 
management of chronic disease (Rochfort et al. 2018). As such, the dissemination of 
PSM skills through primary care should reduce healthcare disparities and the burden 
of non-communicable disease (Bruggink et al. 2019; Department of Health 2019; 
Hardman, Lawn & Tsourtos 2018). 
This interprofessional collaboration developed an innovative approach to a common 
and complex clinical conundrum. Such non-commercial educational research 
partnerships will be unlikely without financial support from health funding bodies 
(Hogans et al. 2018). Since discontinuation of POAs (particularly if non-consensual) 
risks increased harm, more resourcing is required for addiction training and 
management (Kertesz & Gordon 2018). Should regulators mandate periodic training 
in pain and addictions, TEMPO-like education may provide a template (Davis & Carr 
2016). 
To appraise effectiveness, investment in development and validation of an educational 
assessment instrument will be necessary, potentially involving interrogation of GP 
electronic health records and patient-reported functional outcome measures (Hogans 
et al. 2018; Sullivan & Ballantyne 2016). Improved outcomes from training may require 
repeated training exposures, with scaleability enhanced by the utilisation of web-
based formats (Hogans et al. 2018). 
These data reflect real-world GP education, delivered at a mainstream conference. 
Individually matched outcomes were sustainable; the three-month, post-workshop 
gap exceeds most other evaluations of similar interventions. 
A major limitation of the study is the lack of a control group. This workshop 
occurred four months before codeine was ‘up-scheduled’, making it unavailable over 
the counter (Holliday et al. 2018). A control group would have helped to identify bias 
from concurrent training. There is also a risk of sampling bias due to the ALM 
registrants being self-selected. However, the matching of individualised results may 
ameliorate this bias. We also relied on a pragmatic uncontrolled mode of evaluation—
the pre-/post-test, which is the most commonly used instrument evaluating CP 
education (Ospina et al. 2013). Our evaluation instrument was original with moderate 
internal validity. As with the majority of educational evaluations, lack of instrument 
reliability and validity data and modest response rates limits the strength of our 
  
 
Health Education in Practice: Journal of Research for Professional Learning, Vol 3, No. 1, 2020 
 
16 
Holliday et al.  
conclusions (Hogans et al. 2018). That said, our response rate was consistent with 
many surveys of GPs (Bonevski et al. 2011). 
Our pre-readings may have boosted pre-test scores, reducing the apparent effect 
of the package. Further, we did not observe objective clinical behaviour, which may 
be discordant with paper-based self-report (Holliday, Hayes, Dunlop, Morgan, Tapley, 
Henderson, Larance, et al. 2017; Holliday, Hayes, Dunlop, Morgan, Tapley, Henderson, 
van Driel, et al. 2017). Finally, pain and opioid education is ultimately designed to 
improve patient and societal health, neither of which was measured in this evaluation 
(Hogans et al. 2018). 
CONCLUSION 
GPs manage the vast majority of CP and do so without the resources and interventions 
of specialist MDTs. Therefore, an alternative is needed to allow GPs to transition from 
biomedical medication management towards a multifaceted approach. We showed 
that it is feasible to assemble an MDT involving specialist pain practitioners and GPs to 
deliver brief CP training as standard CME to disseminate competencies appropriate for 
a GP’s clinical workflow. Our unvalidated instrument showed modest evidence that 
the training had sustainable value. Three months following the workshop, GPs self-
reported improved knowledge and attitudes as well as increased utilisation of 
multimodal PSM and less reliance on addictive pharmacotherapy. Further studies are 
needed to explore whether PSM training for GPs improves access to affordable holistic 
pain care. Intriguingly, such training may improve outcomes for the common and 
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BOX 2: TIME-EFFICIENT MANAGEMENT OF PAIN IN THE 
OFFICE (TEMPO) 
PRE-WORKSHOP SURVEY 
Thank you for participating in the pre-assessment survey for the Time-efficient 
Management of Pain in the Office (TEMPO) program. It should take you about 15 
minutes to complete. We request that you please answer all questions, so that, with 
the post-assessment survey, we can measure the effectiveness of this educational 
activity. Ethical approval for this evaluation has been given by the RACGP National 
Research and Evaluation Ethics Committee (NREEC) 16-005. 
 
Please complete the following. 
 
Q1 For GPs: RACGP Continuing Medical Education number 
 
  or ACRRM Continuing Medical Education number 
 
  For non-GPs: Please note your profession 
  For non-GPs: Specialty Continuing Education number 
Q2 What is your gender? 
Q3 What is your age? 
Q4 Postcode of your main practice address 
Q5 Circle one only: Are you registered with the Prescription Shopping Information 
Service (or for Tasmanians, the Drugs and Poisons Information System Online Remote 
Access [DORA])? 
 
a) Yes, and use it often 
b) Yes, but rarely use it 
c) No, not registered 
 
For the following questions, please give your initial responses without dwelling on any 
question. 
 
Q6 Circle one only: The initial assessment of chronic non-cancer pain patients 
should routinely cover all of the following EXCEPT: 
a) sleep 
b) depression 
c) diagnostic imaging 
d) concerns and fears 
e) drug and medication history 
(Answer: c) 
Q7 Circle one only: Chronic non-cancer pain patient education explains that … 
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a) pharmaceuticals have a limited role 
b) long-term opioid treatment is only effective as a last resort 
c) sedentary behaviour may prevent disease progression 
d) pain flare-ups indicate tissue damage 
(Answer: a) 
Q8 Circle one only: In the self-management of chronic non-cancer pain, an 
important aspect for patients is … 
a) learning that worse things have happened to other people 
b) regulating interfering thoughts and feelings 
c) learning to follow the doctor’s instructions 
d) accepting that suffering is mental, not physical 
e) accepting that you cannot wind back the clock 
(Answer: b) 
Q9 Circle one only: Activity pacing means encouraging patients to … 
a) gradually build up activity, taking regular breaks 
b) keep pushing harder: ‘no pain, no gain’ 
c) increase the duration of rest with increasing durations of activity 
d) stop the activity whenever the pain gets too much 
e) increase rest and recovery 
(Answer: a) 
Q10 Circle one only: Insomnia in patients experiencing chronic non-cancer pain 
requires … 
a) ‘Z-drugs’ (e.g., zolpidem or zopiclone) at higher doses 
b) a referral to a sleep specialist 
c) a judicious balance of benzodiazepines and opioids 
d) sleep-restriction strategies 
e) opioid analgesia to precede any non-pharmacological management 
(Answer: d) 
Q11 Circle one only: When managing chronic non-cancer pain … 
a) self-medication of pain with alcohol may worsen pain outcome scores 
b) smoking cessation should be delayed pending effective pain control 
c) stimulating SSRIs are preferred to increase activity levels 
d) muscular and psychological tension are improved by benzodiazepines 
f) there is strong evidence to support the medical prescription of cannabis 
(Answer: a) 
Q12 Circle one only: Supporting self-management of chronic non-cancer pain 
involves the doctor … 
a) confronting patients about the dangers of their risky choices 
b) always being enthusiastic and positive 
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c) always expressing your frustration if patients fail to practise agreed tasks 
d) focusing in-depth on patient defences 
e) exploring patients’ hopes and goals 
(Answer: e) 
Q13 Circle one only: Regarding prescribed opioids in chronic non-cancer pain … 
a) patients describing severe genuine pain have a right to opioid painkillers 
b) reserve psychological interventions for those with psychiatric illnesses 
c) tolerance or hyperalgesia is unlikely in the treatment of genuine pain 
d) overdose is a risk in those taking long-term opioids, as prescribed 
e) reserve urine drug tests for patients where there is suspicion of drug or 
medication abuse 
(Answer: d) 
Q14 Circle one only: If starting opioid analgesic prescription for chronic non-cancer 
pain … 
a) patients must sign a legal contract that states their opposition to addiction 
b) imaging must have shown an anatomically verified diagnosis 
c) there cannot be any past or present substance use disorders 
d) codeine or tramadol are always a safe choice 
e) all of the above 
f) none of the above 
(Answer: f) 
Q15 Circle one only: Opioid analgesics in chronic non-cancer pain will be safe if … 
a) patients are regularly monitored for medication misuse 
b) patient assessment shows they are at low risk of medication abuse 
c) patients are not identified as doctor shoppers 
d) patients are kept on lower opioid doses 
e) all of the above 
f) none of the above 
(Answer: f) 
Q16 Circle one only: Your patient increased his/her opioid dose because his/her 
pain is ‘10 out of 10’ and he/she appears oversedated. What would you do? 
a) increase dose of opioid because he/she still has severe pain 
b) continue current opioid dose until tolerance to sedation is reached 
c) decrease current opioid dose because of his/her oversedation 
d) stop the current opioid because the patient is likely addicted 
(Answer: c) 
This section is designed to assess your clinical opinions and experience with chronic 
non-cancer pain patients. Using the five-point scale provided, where 1 = completely 
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disagree and 5 = completely agree, please indicate your level of agreement with the 
following statements: 
 
Q17 Please circle the number in the right-hand column to indicate your response to 
each question. (target answer is answer 5 unless it is reverse scored) 












a) treating chronic non-cancer 
pain patients is time-consuming 
and frustrating (reverse 
scored) 
1 2 3 4 5 
b) pain scales help me monitor 
my patients’ management 
1 2 3 4 5 
c) I am comfortable discussing 
patients’ unhelpful thoughts 
1 2 3 4 5 
d) I am comfortable coaching 
patients regarding their activity 
levels 
1 2 3 4 5 
e) pain patients are rarely 
truthful about illicit drug use 
(reverse scored) 
1 2 3 4 5 
f) I am comfortable discussing 
naloxone rescue kits 
1 2 3 4 5 
g) I prefer to stop 
seeing/following a patient who 
has misused his/her opioid 
prescription (reverse scored) 
1 2 3 4 5 
h) I am comfortable asking for a 
urine drug test from a patient 
who does not seem to be 
abusing their opioid prescription 
1 2 3 4 5 
i) I am comfortable with making 
opioid prescribing more 
restrictive if there is any abuse 
or dependency risk 
1 2 3 4 5 
j) I am comfortable shifting away 
from opioids towards active self-
care 
1 2 3 4 5 
k) non-pharmacological pain 
approaches generally are 
ineffective (reverse scored) 
1 2 3 4 5 
Q18 Please tick the appropriate box for each question. 
Currently, with patients 
experiencing chronic non-

















a) taking a psychiatric and 
psychological history 
 
   
 
b) taking a drug and alcohol 
history including addictive 
pharmaceuticals 
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Currently, with patients 
experiencing chronic non-

















c) using a pain outcome 
measurement scale 
 
   
 
d) facilitating establishment of 
achievable functional goals 
 
   
 
e) providing fast breathing 
education for self-management 
of flare-ups (reverse scored) 
 
   
 
f) exploring how emotions and 
thoughts affect physical 
symptoms 
 
   
 
g) prescribing long-term opioid 
analgesics (reverse scored) 
 
   
 
h) providing education about the 
neuroscience of chronic pain 
 
   
 
i) assessing activity or inactivity  
   
 
 
Q19 Please tick the appropriate box for each question. 
Over the last couple of 
months with patients 
experiencing chronic non-
cancer pain on long-term 

















a) discussing their side effects      
b) prescribing a benzodiazepine for 
insomnia (reverse scored) 
 
   
 
c) starting a conversation about 
opioid reduction 
 
   
 
d) seeking regulatory approval 
(where required) 
 
   
 
e) warning patients that anyone 
who misuses their analgesics will 
be fired from the practice (reverse 
scored) 
 
   
 
f) considering naloxone 
prescription 
 
   
 
g) assessing suicide risk 
 
   
 
Q20 Please tick the appropriate box: I understand these results will be de-identified 
and analysed to evaluate this educational project. Are you willing for your responses 
to be used for research purposes? 
 
   Yes 
    
No 
 
Please return this survey prior to the workshop. See over for details. Thank you.
